BillionToOne Beats on Q3 Revenue, Lifts 2026 Outlook to $460-470M
BLLN sits 93% above its 52-week low of $61.96.
Summary
BillionToOne delivered Q3 2026 revenue of $123.0 million, up 47% from $83.5 million a year ago, with oncology testing revenue nearly doubling to $17.1 million. Net income jumped to $17.4 million, or $0.32 per diluted share, versus $1.5 million a year earlier, and gross margin held at 71%. The company raised full-year 2026 revenue guidance to $460-470 million from $450-465 million, implying 51-54% growth, and said it expects profitability similar to current levels even with heavy investment. Management also flagged the December 15, 2026 commercial launch of Northstar Clear, a tissue-free MRD test for all solid tumors, extending the oncology franchise. This is the first quarterly report since the Q2 print showed $109.4 million in revenue and a swing to profitability, so the sequential acceleration and guidance raise reinforce the growth story.
At the time of this announcement, BLLN was trading at $119.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $61.96 to $150.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.